Operations Manager21 Jun 2023 18:47
Stephen serves as our Operations Manager having been involved in SkinBioTherapeutics before its start-up and during its subsequent growth phases. He has broad experience in strategic planning, deal structuring, corporate development, and portfolio management in the biotechnology and healthcare industries.
Prior to SkinBioTherapeutics, Stephen built and managed a portfolio of over 25 Healthcare businesses. Spanning therapeutics, medical device, and consumer product sectors Stephen was responsible for leading on business development, commercial partnerships, financing, and the delivery of new technology concepts into development and clinic trials. Stephen has worked in the Pharmaceutical industry with AstraZeneca Plc where he was involved in the delivery of the business’s personalised medicine activities. Stephen has founded two Biotechnology businesses, both of which are in late-stage clinical trials (Phase IIa/b).
Stephen completed postdoctoral work in oncology at the University of Glasgow and in haematology at Harvard Medical School. He holds a Ph.D. in Molecular and Cellular Oncology from the University of Glasgow.
Stephen France has a background in developing new product concepts based on emerging market trends.
His experience spans business operations, technology licensing and investment funding in the life sciences
and pharmaceutical industry. As a venture manager at UMI3 Ltd he led the formation and operational start-up
of a portfolio of venture backed biotechnology companies, including Gelexir Healthcare, Spectromics Ltd,
IF Sensing Ltd, Bioxydyn Ltd, Manchester Imaging Ltd, Clin-e-cal Ltd and Renephra Ltd. He was also
previously a director of Curapel Limited, a specialist dermatology business, where he supported the
translation of the businesses technology pipeline from the laboratory bench, through development and into
human studies. He has a PhD in molecular cancer biology from the University of Glasgow, carried out
postdoctoral research at Harvard University (USA) and has worked in the pharmaceutical industry with
AstraZeneca PLC.
From admission document
Consultants Agreements
Dr Stephen France
On 29 March 2017, the Company entered into a consultancy agreement with Dr France. Dr France provides consultancy services to the Company on regulatory matters. Under the consultancy agreement a daily rate of £500 is payable to Dr France by the Company. Dr. France is eligible to participate in the CSOP referred to in paragraph 8 of this Part VI, and may be
eligible to participate in any additional incentive or similar plan operated by the Company.
On Admission, the Board will exercise its discretion and pay Dr France an Admission Fee of £15,000.
On Admission, Dr France will be granted share options over 0.5 per cent. of the Enlarged Share Capital of the Company.
just a bit of research from whence we came and ongoing team
mol
Sign In
Follow the stocks
